ReviewBritish medical bulletin2013
The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential.
Review in British medical bulletin, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Consequences of Aging on Bone.Aging and disease · 2023Pooled it
- Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review.International journal of medical sciences · 2021Pooled it
- Evaluation of bone marrow-derived cell-based therapies in the hindlimb ischaemia model: a protocol for a systematic review and meta-analysis.BMJ open science · 2021Pooled it
- Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study.Cancer research and treatment · 2022Trial
- Type 2 Diabetes Modulates Mesenchymal Stem Cell Response to Advanced Glycation End Products and N-Acetylcysteine Antioxidant Effect.Pharmaceutics · 2026Article
- Epigenetic transcriptional regulation of skeletal aging: The emerging role of mJournal of orthopaedic translation · 2026Review
- Pre-vascularized enhances therapeutic effects of human bone marrow-derived mesenchymal stem cell sheets in Buccal Mucosa wound.BMC oral health · 2026Article
- Perspective in 3D mesenchymal stromal cells as tools for potential diabetes treatment.Research in pharmaceutical sciences · 2026Review
- Harnessing MSC Immunomodulation in Orthopedics: Clinical Insights for Comorbidities.Stem cell reviews and reports · 2026Review
- A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous UMC119-06 in Patients with Acute Ischemic Stroke.International journal of medical sciences · 2026Article
- Progress and prospect of minicircle as a minimized non-viral DNA vector in gene therapy and regenerative medicine.Molecular therapy. Nucleic acids · 2025Review
- Gestational Diabetes Exposed Mesenchymal Stem Cells: Phenotypic Differences Link to Long-Term Health of Offspring.International journal of molecular sciences · 2025Review
- Stem cell modelling of osteoarthritis using an organ-on-a-chip approach.Inflammation and regeneration · 2025Article
- Stem cell therapy in systemic sclerosis.Clinical rheumatology · 2025Review
- Exosomes derived from human amniotic mesenchymal stem cells promotes angiogenesis in hUVECs by delivering novel miRNA N-194.Molecular medicine (Cambridge, Mass.) · 2025Article
- Immune and Angiogenic Profiling of Mesenchymal Stem Cell Functions in a Subcutaneous Microenvironment for Allogeneic Islet Transplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Functional impacts of lactylation in Hypoxia‒primed mesenchymal stromal cells.Frontiers in cell and developmental biology · 2025Review
- Therapeutic Applications of Engineered Mesenchymal Stromal Cells for Enhanced Angiogenesis in Cardiac and Cerebral Ischemia.Stem cell reviews and reports · 2024Review
- Characterization and angiogenic potential of CD146Stem cell research & therapy · 2024Article
- In vitro biomaterial priming of human mesenchymal stromal/stem cells : implication of the Src/JAK/STAT3 pathway in vasculogenic mimicry.Scientific reports · 2024Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBlood vessel formation is fundamental to development, while its dysregulation can contribute to serious disease. Expectations are that hundreds of millions of individuals will benefit from therapeutic developments in vascular biology. MSCs are central to the three main vascular repair mechanisms. SOURCES OF DATA: Key recent published literature and ClinicalTrials.gov. AREAS OF AGREEMENT: MSCs are heterogeneous, containing multi-lineage stem and partly differentiated progenitor cells, and are easily expandable ex vivo. There is no single marker defining native MSCs in vivo. Their phenotype is strongly determined by their specific microenvironment. Bone marrow MSCs have skeletal stem cell properties. Having a perivascular/vascular location, they contribute to vascular formation and function and might be harnessed to regenerate a blood supply to injured tissues. AREAS OF CONTROVERSY: These include MSC origin, phenotype and location in vivo and their ability to differentiate into functional cardiomyocytes and endothelial cells or act as vascular stem cells. In addition their efficacy, safety and potency in clinical trials in relation to cell source, dose, delivery route, passage and timing of administration, but probably even more on the local preconditioning and the mechanisms by which they exert their effects. GROWING POINTS: Understanding the origin and the regenerative environment of MSCs, and manipulating their homing properties, proliferative ability and functionality through drug discovery and reprogramming strategies are important for their efficacy in vascular repair for regenerative medicine therapies and tissue engineering approaches. AREAS TIMELY FOR DEVELOPING RESEARCH: Characterization of MSCs' in vivo origins and biological properties in relation to their localization within tissue niches, reprogramming strategies and newer imaging/bioengineering approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.